PMC:7195088 / 31410-33620 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T38","span":{"begin":1288,"end":1301},"obj":"Body_part"},{"id":"T39","span":{"begin":1288,"end":1299},"obj":"Body_part"},{"id":"T40","span":{"begin":1324,"end":1332},"obj":"Body_part"},{"id":"T41","span":{"begin":1595,"end":1599},"obj":"Body_part"},{"id":"T42","span":{"begin":1595,"end":1597},"obj":"Body_part"},{"id":"T43","span":{"begin":2184,"end":2190},"obj":"Body_part"}],"attributes":[{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A40","pred":"fma_id","subj":"T40","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma228738"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T24","span":{"begin":160,"end":165},"obj":"Body_part"},{"id":"T25","span":{"begin":221,"end":226},"obj":"Body_part"},{"id":"T26","span":{"begin":616,"end":621},"obj":"Body_part"},{"id":"T27","span":{"begin":2184,"end":2190},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"uberon_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A25","pred":"uberon_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A26","pred":"uberon_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"},{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":1089,"end":1095},"obj":"Phenotype"},{"id":"T31","span":{"begin":1967,"end":1976},"obj":"Phenotype"},{"id":"T32","span":{"begin":2051,"end":2056},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T162","span":{"begin":66,"end":74},"obj":"Disease"},{"id":"T163","span":{"begin":323,"end":331},"obj":"Disease"},{"id":"T164","span":{"begin":499,"end":507},"obj":"Disease"},{"id":"T165","span":{"begin":760,"end":768},"obj":"Disease"},{"id":"T166","span":{"begin":1078,"end":1095},"obj":"Disease"},{"id":"T167","span":{"begin":1089,"end":1095},"obj":"Disease"},{"id":"T168","span":{"begin":1100,"end":1108},"obj":"Disease"},{"id":"T169","span":{"begin":1387,"end":1395},"obj":"Disease"},{"id":"T170","span":{"begin":1733,"end":1741},"obj":"Disease"},{"id":"T171","span":{"begin":1958,"end":1966},"obj":"Disease"},{"id":"T172","span":{"begin":1967,"end":1976},"obj":"Disease"},{"id":"T173","span":{"begin":2107,"end":2119},"obj":"Disease"}],"attributes":[{"id":"A162","pred":"mondo_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A163","pred":"mondo_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A164","pred":"mondo_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0024880"},{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T175","span":{"begin":81,"end":86},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T176","span":{"begin":202,"end":206},"obj":"http://purl.obolibrary.org/obo/CLO_0001550"},{"id":"T177","span":{"begin":338,"end":343},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T178","span":{"begin":598,"end":601},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"},{"id":"T179","span":{"begin":775,"end":780},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T180","span":{"begin":840,"end":841},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T181","span":{"begin":887,"end":888},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T182","span":{"begin":1115,"end":1120},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T183","span":{"begin":1288,"end":1301},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T184","span":{"begin":1402,"end":1407},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T185","span":{"begin":1748,"end":1753},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T186","span":{"begin":1983,"end":1988},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T187","span":{"begin":2048,"end":2049},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T188","span":{"begin":2094,"end":2095},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T423","span":{"begin":16,"end":27},"obj":"Chemical"},{"id":"T424","span":{"begin":81,"end":86},"obj":"Chemical"},{"id":"T425","span":{"begin":245,"end":256},"obj":"Chemical"},{"id":"T426","span":{"begin":261,"end":272},"obj":"Chemical"},{"id":"T427","span":{"begin":277,"end":288},"obj":"Chemical"},{"id":"T428","span":{"begin":294,"end":305},"obj":"Chemical"},{"id":"T429","span":{"begin":338,"end":343},"obj":"Chemical"},{"id":"T430","span":{"begin":445,"end":456},"obj":"Chemical"},{"id":"T431","span":{"begin":649,"end":660},"obj":"Chemical"},{"id":"T432","span":{"begin":666,"end":684},"obj":"Chemical"},{"id":"T433","span":{"begin":690,"end":702},"obj":"Chemical"},{"id":"T434","span":{"begin":707,"end":718},"obj":"Chemical"},{"id":"T435","span":{"begin":724,"end":742},"obj":"Chemical"},{"id":"T436","span":{"begin":775,"end":780},"obj":"Chemical"},{"id":"T437","span":{"begin":970,"end":981},"obj":"Chemical"},{"id":"T438","span":{"begin":1002,"end":1013},"obj":"Chemical"},{"id":"T439","span":{"begin":1115,"end":1120},"obj":"Chemical"},{"id":"T440","span":{"begin":1211,"end":1222},"obj":"Chemical"},{"id":"T441","span":{"begin":1241,"end":1252},"obj":"Chemical"},{"id":"T442","span":{"begin":1402,"end":1407},"obj":"Chemical"},{"id":"T443","span":{"begin":1505,"end":1511},"obj":"Chemical"},{"id":"T444","span":{"begin":1557,"end":1568},"obj":"Chemical"},{"id":"T445","span":{"begin":1595,"end":1597},"obj":"Chemical"},{"id":"T447","span":{"begin":1609,"end":1619},"obj":"Chemical"},{"id":"T448","span":{"begin":1683,"end":1694},"obj":"Chemical"},{"id":"T449","span":{"begin":1748,"end":1753},"obj":"Chemical"},{"id":"T450","span":{"begin":1892,"end":1911},"obj":"Chemical"},{"id":"T451","span":{"begin":1892,"end":1901},"obj":"Chemical"},{"id":"T452","span":{"begin":1902,"end":1911},"obj":"Chemical"},{"id":"T453","span":{"begin":1915,"end":1925},"obj":"Chemical"},{"id":"T454","span":{"begin":1929,"end":1940},"obj":"Chemical"},{"id":"T455","span":{"begin":1983,"end":1988},"obj":"Chemical"}],"attributes":[{"id":"A423","pred":"chebi_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A424","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A425","pred":"chebi_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A426","pred":"chebi_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A427","pred":"chebi_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A428","pred":"chebi_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A429","pred":"chebi_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A430","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A431","pred":"chebi_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A432","pred":"chebi_id","subj":"T432","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A433","pred":"chebi_id","subj":"T433","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A434","pred":"chebi_id","subj":"T434","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A435","pred":"chebi_id","subj":"T435","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A436","pred":"chebi_id","subj":"T436","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A437","pred":"chebi_id","subj":"T437","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A438","pred":"chebi_id","subj":"T438","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A439","pred":"chebi_id","subj":"T439","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A440","pred":"chebi_id","subj":"T440","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A441","pred":"chebi_id","subj":"T441","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A442","pred":"chebi_id","subj":"T442","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A443","pred":"chebi_id","subj":"T443","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A444","pred":"chebi_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A445","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A446","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A447","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A448","pred":"chebi_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A449","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A450","pred":"chebi_id","subj":"T450","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A451","pred":"chebi_id","subj":"T451","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A452","pred":"chebi_id","subj":"T452","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A453","pred":"chebi_id","subj":"T453","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A454","pred":"chebi_id","subj":"T454","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A455","pred":"chebi_id","subj":"T455","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T12","span":{"begin":2107,"end":2119},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}

{"project":"LitCovid-sentences","denotations":[{"id":"T246","span":{"begin":76,"end":125},"obj":"Sentence"},{"id":"T247","span":{"begin":126,"end":228},"obj":"Sentence"},{"id":"T248","span":{"begin":229,"end":332},"obj":"Sentence"},{"id":"T249","span":{"begin":333,"end":374},"obj":"Sentence"},{"id":"T250","span":{"begin":375,"end":428},"obj":"Sentence"},{"id":"T251","span":{"begin":429,"end":508},"obj":"Sentence"},{"id":"T252","span":{"begin":509,"end":560},"obj":"Sentence"},{"id":"T253","span":{"begin":561,"end":632},"obj":"Sentence"},{"id":"T254","span":{"begin":633,"end":769},"obj":"Sentence"},{"id":"T255","span":{"begin":770,"end":819},"obj":"Sentence"},{"id":"T256","span":{"begin":820,"end":953},"obj":"Sentence"},{"id":"T257","span":{"begin":954,"end":1109},"obj":"Sentence"},{"id":"T258","span":{"begin":1110,"end":1159},"obj":"Sentence"},{"id":"T259","span":{"begin":1160,"end":1177},"obj":"Sentence"},{"id":"T260","span":{"begin":1178,"end":1194},"obj":"Sentence"},{"id":"T261","span":{"begin":1195,"end":1396},"obj":"Sentence"},{"id":"T262","span":{"begin":1397,"end":1446},"obj":"Sentence"},{"id":"T263","span":{"begin":1447,"end":1540},"obj":"Sentence"},{"id":"T264","span":{"begin":1541,"end":1742},"obj":"Sentence"},{"id":"T265","span":{"begin":1743,"end":1792},"obj":"Sentence"},{"id":"T266","span":{"begin":1793,"end":1860},"obj":"Sentence"},{"id":"T267","span":{"begin":1861,"end":1977},"obj":"Sentence"},{"id":"T268","span":{"begin":1978,"end":2027},"obj":"Sentence"},{"id":"T269","span":{"begin":2028,"end":2210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• Comparison of tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04331808, not yet recruiting). Primary endpoint: WHO progression scale at day 7 and 14 (severity rating on a 10-point ordinal scale).\n• Comparison of favipiravir vs. tocilizumab vs. favipiravir plus tocilizumab in patients with COVID-19. Open-label RCT (NCT04310228, recruiting). Primary endpoint: clinical cure (follow-up 3 months).\n• Comparison of tocilizumab vs. placebo in hospitalized patients with COVID-19. Double-blind RCT (NCT04320615, not yet recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 28.\n• Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. Open-label RCT (NCT04332094, not yet recruiting). Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).\n• Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival.\n• Comparison of tocilizumab intravenously vs. tocilizumab subcutaneously vs. sarilumab (anti-interleukin 6 receptor α monoclonal antibody) subcutaneously vs. standard of care in patients with COVID-19. Open-label RCT (NCT04322773, not yet recruiting). Primary endpoint: time to independence from supplementary oxygen therapy (follow-up 28 days).\n• Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days).\n• Comparison of carrimycin vs. lopinavir/ritonavir or umifenovir or chloroquine in patients with COVID-19 pneumonia. Open-label RCT (NCT04286503, not yet recruiting). Primary endpoints: (a) fever to normal time (follow-up 30 days); (b) pulmonary inflammation resolution time (follow-up 30 days); (c) negative conversion of throat swab RT-PCR at EOT."}